Tag archive for ‘Veltassa March 2016 results’
Relypsa: Analyzing March Results of the Veltassa Launch (RLYP, Buy, $17.60)
Investment Perspective Investors are closely watching the launch progress of Veltassa following its December 2015 introduction. Medicare and managed care have set up barriers to prescribing that makes getting a prescription filled for a new drug laborious and time consuming and sometimes futile. With very few exceptions, most new product launches have disappointed investors to […]